NOVN.SW Novartis (SIX) at CHF126.48 intraday 24 Feb 2026: watch pipeline catalysts

We note NOVN.SW stock trading at CHF126.48 intraday on 24 Feb 2026, driven by heavy activity on the SIX exchange. Volume stands at 2,517,608 shares, making Novartis one of the most active names in Swiss healthcare today. Price has oscillated between CHF126.16 and CHF128.08 so far. We focus on clinical catalysts, earnings timing, and valuation metrics that connect recent news to the stock move. As an AI-powered market analysis platform, Meyka AI tracks these inputs in real time for traders and investors.

NOVN.SW stock intraday snapshot

Novartis AG (NOVN.SW) is trading at CHF126.48 on the SIX exchange. Intraday range is CHF126.16–CHF128.08 and the previous close was CHF126.46. Volume is 2,517,608 versus an average of 3,213,749, so activity is elevated relative to Swiss healthcare peers. Year high is CHF129.54 and year low is CHF81.10. The stock remains well above its 50-day average of CHF115.25 and 200-day average of CHF103.33, showing persistent upside pressure during the trading session.

NOVN.SW stock news and near-term catalysts

Recent clinical and corporate news is the main catalyst for intraday interest in NOVN.SW stock. Novartis posted Phase III wins for remibrutinib (Rhapsido®) in chronic inducible urticaria and presented multiple abstracts at AAAAI. The company also reported Phase III data for Vanrafia® in IgA nephropathy. Management flagged a low single-digit decline in 2026 operating profit due to generic competition, and announced the planned sale of its 70.68% stake in the Indian business. For company releases and coverage see the Novartis website and market pages, including Reuters reporting source and company information at Novartis. These items explain why trading is concentrated ahead of the 2026 earnings announcement on 28 Apr 2026.

NOVN.SW stock fundamentals and valuation

Novartis shows steady fundamentals that support the current price. Trailing EPS is 5.50 CHF and the trailing PE is 23.27. Key ratios include Price/Sales 5.61, Price/Book 6.86, and Free Cash Flow yield 5.31%. Net debt metrics show netDebt/EBITDA 1.12 and debt/equity 0.80, giving the balance sheet moderate leverage. Return on equity is strong at 32.80% and operating margin sits near 31.24%. Dividend per share is CHF4.52, implying a yield of 2.73% at today’s price. These metrics explain why many investors view NOVN.SW stock as a defensive growth name in healthcare.

Technical view on NOVN.SW stock

Technically, NOVN.SW stock is in a strong uptrend. Price sits above the 50-day average CHF115.25 and 200-day average CHF103.33. Momentum reads RSI 78.04, indicating overbought conditions intraday. MACD is positive with MACD 3.73 and signal 3.36, and Bollinger Bands show upper band near CHF130.92. ATR is CHF2.10, showing moderate volatility. These indicators suggest possible short-term consolidation, but the trend and volume profile support further upside if clinical or earnings news remains positive.

Meyka AI rates NOVN.SW with a score out of 100 and forecast

Meyka AI rates NOVN.SW with a score out of 100: 77.68, Grade B+ — Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Our model highlights strong ROE, free cash flow, and pipeline momentum, offset by patent and generic risks.

Meyka AI’s forecast model projects a near-term quarterly price of CHF127.28 and a five-year target of CHF140.37. Versus the current CHF126.48, the quarterly projection implies +0.63% upside and the five-year projection implies +10.98% upside. Forecasts are model-based projections and not guarantees. For positioning, traders should weigh catalysts against valuation and the upcoming earnings date on 28 Apr 2026.

Positioning, risks and recommended monitoring

Investors should monitor regulatory and clinical readouts, the Indian stake sale execution, and U.S. tariff exposure updates. Key risks include generic erosion of legacy medicines and single-study setbacks in late-stage trials. On the other side, successful launches of remibrutinib or Vanrafia could drive conviction. For intraday traders, keep stops near CHF126.16 and watch volume spikes near the CHF129.54 supply zone.

Final Thoughts

NOVN.SW stock is one of the most active healthcare names on the SIX intraday tape at CHF126.48 and 2,517,608 shares traded. Price action reflects a mix of favourable Phase III data and corporate moves, including the Indian stake sale and U.S. manufacturing updates. Fundamentals show a solid PE 23.27, EPS 5.50, and FCF yield 5.31%, which support a defensive-growth thesis. Meyka AI’s forecast model projects CHF127.28 over the quarter and CHF140.37 over five years, implying +0.63% and +10.98% upside respectively from today’s price. These projections guide a watchful stance: NOVN.SW stock looks structurally sound, but near-term returns will hinge on pipeline readouts and margin guidance. Use earnings on 28 Apr 2026 and upcoming trial data to reassess risk and position size.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.